Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 232
9
Diseases
23
Unique genes
0.295
Avg. similarity score
Holoprosencephaly 3
Most-connected disease (5 links)
Disease
Searched: Frank-ter haar syndrome
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Frank-ter haar syndrome
Holoprosencephaly 3
Microphthalmia with coloboma 5
Partial agenesis of corpus callosum
Preaxial polydactyly with upper back hypertrichosis
Schizencephaly
Solitary median maxillary central incisor
Eye abnormalities
Neurodevelopmental disorder with severe motor impairment and absent language
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Holoprosencephaly 3 | 5 | 5 | 1 |
| Microphthalmia with coloboma 5 | 5 | 5 | 1 |
| Partial agenesis of corpus callosum | 5 | 5 | 3 |
| Preaxial polydactyly with upper back hypertrichosis | 5 | 5 | 1 |
| Schizencephaly | 5 | 5 | 5 |
| Solitary median maxillary central incisor | 5 | 5 | 1 |
| Eye abnormalities | 2 | 2 | 17 |
| Frank-ter haar syndrome | 1 | 1 | 1 |
| Neurodevelopmental disorder with severe motor impairment and absent language | 1 | 1 | 2 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| SHH | 7 / 9 | Eye abnormalities, Holoprosencephaly 3, Microphthalmia with coloboma 5, Partial agenesis of corpus callosum and 3 more |
| COL4A1 | 2 / 9 | Eye abnormalities, Schizencephaly |
| SH3PXD2B | 2 / 9 | Eye abnormalities, Frank-ter haar syndrome |
| TAF8 | 2 / 9 | Neurodevelopmental disorder with severe motor impairment and absent language, Partial agenesis of corpus callosum |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Pathways in cancer | KEGG | 9 / 533 | 8.8× | 2.92e-7 | 1.35e-5 ✓ sig. |
| Hippo signaling pathway | KEGG | 5 / 157 | 16.6× | 9.96e-6 | 2.70e-4 ✓ sig. |
| Colorectal cancer | KEGG | 4 / 87 | 24.0× | 2.05e-5 | 4.88e-4 ✓ sig. |
| AGE-RAGE signaling pathway in diabetic complications | KEGG | 4 / 101 | 20.7× | 3.69e-5 | 7.89e-4 ✓ sig. |
| TGF-beta signaling pathway | KEGG | 4 / 108 | 19.3× | 4.80e-5 | 9.81e-4 ✓ sig. |
| Gastric cancer | KEGG | 4 / 150 | 13.9× | 1.72e-4 | 2.72e-3 ✓ sig. |
| Signaling by BMP | Reactome | 2 / 28 | 37.3× | 1.29e-3 | 1.31e-2 ✓ sig. |
| APC truncation mutants are not K63 polyubiquitinated | Reactome | 1 / 1 | 522× | 1.92e-3 | 1.76e-2 ✓ sig. |
| Cytokine-cytokine receptor interaction | KEGG | 4 / 298 | 7.0× | 2.27e-3 | 1.99e-2 ✓ sig. |
| Signaling pathways regulating pluripotency of stem cells | KEGG | 3 / 144 | 10.9× | 2.51e-3 | 2.15e-2 ✓ sig. |
| Hepatitis B | KEGG | 3 / 163 | 9.6× | 3.56e-3 | 2.76e-2 ✓ sig. |
| TGFBR2 MSI Frameshift Mutants in Cancer | Reactome | 1 / 2 | 261× | 3.83e-3 | 2.90e-2 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 3 / 170 | 9.2× | 4.01e-3 | 3.00e-2 ✓ sig. |
| Axon guidance | KEGG | 3 / 183 | 8.6× | 4.92e-3 | 3.47e-2 ✓ sig. |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | Reactome | 1 / 3 | 174× | 5.73e-3 | 3.84e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of cell population proliferation | GO:0042127 | 6 / 201 | 24.3× | 1.25e-7 | 1.51e-5 ✓ sig. |
| eye development | GO:0001654 | 4 / 49 | 66.3× | 3.56e-7 | 3.61e-5 ✓ sig. |
| cardiac right ventricle morphogenesis | GO:0003215 | 3 / 13 | 187× | 4.62e-7 | 4.50e-5 ✓ sig. |
| heart development | GO:0007507 | 6 / 273 | 17.9× | 7.54e-7 | 6.73e-5 ✓ sig. |
| optic vesicle morphogenesis | GO:0003404 | 2 / 2 | 812× | 1.45e-6 | 1.15e-4 ✓ sig. |
| roof of mouth development | GO:0060021 | 4 / 70 | 46.4× | 1.51e-6 | 1.19e-4 ✓ sig. |
| endocardial cushion morphogenesis | GO:0003203 | 3 / 19 | 128× | 1.56e-6 | 1.22e-4 ✓ sig. |
| camera-type eye development | GO:0043010 | 4 / 74 | 43.9× | 1.89e-6 | 1.42e-4 ✓ sig. |
| forebrain development | GO:0030900 | 4 / 76 | 42.8× | 2.11e-6 | 1.55e-4 ✓ sig. |
| cellular response to growth factor stimulus | GO:0071363 | 4 / 76 | 42.8× | 2.11e-6 | 1.55e-4 ✓ sig. |
| positive regulation of mesenchymal cell proliferation | GO:0002053 | 3 / 26 | 93.7× | 4.16e-6 | 2.66e-4 ✓ sig. |
| outflow tract septum morphogenesis | GO:0003148 | 3 / 28 | 87.1× | 5.23e-6 | 3.20e-4 ✓ sig. |
| embryonic forelimb morphogenesis | GO:0035115 | 3 / 33 | 73.9× | 8.67e-6 | 4.77e-4 ✓ sig. |
| cell surface receptor protein serine/threonine kinase signaling pathway | GO:0007178 | 3 / 33 | 73.9× | 8.67e-6 | 4.77e-4 ✓ sig. |
| branching involved in blood vessel morphogenesis | GO:0001569 | 3 / 33 | 73.9× | 8.67e-6 | 4.77e-4 ✓ sig. |